iBio Fibrosis Therapeutics Program Receives NIH Grant Support - Seite 2

iBio is sponsoring research and development at both MUSC and Novici in a coordinated program focused on IBIO-CFB03 and potentially other product candidates. In particular, the collaboration with Novici has focused on overcoming the limitations of chemical peptide synthesis by using the iBioLaunch technology for recombinant peptide production in plants. Ongoing collaborative work at MUSC has demonstrated that recombinant versions of the peptides duplicate the preventative and disease-modifying properties of chemically-synthesized peptides. Additional joint work includes testing novel product formulations that may yield improved performance. The company has also established contracts with CBR International for regulatory management services and with Caliber Biotherapeutics LLC for cGMP manufacturing services.

About The Medical University of South Carolina
Founded in 1824 in Charleston, The Medical University of South Carolina is the oldest medical school in the South. Today, MUSC continues the tradition of excellence in education, research, and patient care. MUSC educates and trains more than 3,000 students and residents, and has nearly 13,000 employees, including approximately 1,500 faculty members. As the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $1.7 billion. MUSC operates a 750-bed medical center, which includes a nationally recognized Children's Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (one of 68 National Cancer Institute designated centers) Level I Trauma Center and Institute of Psychiatry. For more information on academic information or clinical services, visit musc.edu. For more information on hospital patient services, visit www.muschealth.org .

About Novici Biotech LLC
Novici is a private biotechnology company working at the intersection of synthetic biology and recombinant expression. Combining its strengths in plant-based expression with its patented GRAMMR gene shuffling technology, the company is focused on improving recombinant protein function as well as expression yield through directed evolution. Beyond pharmaceutical applications, Novici utilizes the GRAMMR technology for improvement of agricultural and industrial biotechnology targets and also out-licenses other synthetic biology tools, such as the CorrectASE synthetic gene error correction product, currently offered for sale by ThermoFisher Scientific. For more information, visit www.novicibiotech.com .